Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)

Four burn­ing ques­tions about the fu­ture of the $16.5B No­vo-Catal­ent deal

To build or to buy? That’s a clas­sic ques­tion for phar­ma board­rooms, and No­vo Nordisk is go­ing with both.

Be­yond spend­ing bil­lions of dol­lars to ex­pand its own pro­duc­tion ca­pac­i­ty for its weight loss drugs, the Dan­ish drug­mak­er said Mon­day it will pay $11 bil­lion to ac­quire three man­u­fac­tur­ing plants from Catal­ent. It’s part of a broad­er $16.5 bil­lion deal with No­vo Hold­ings, the in­vest­ment arm of the phar­ma’s par­ent group, which agreed to ac­quire the con­tract man­u­fac­tur­er and take it pri­vate.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA